0FP0 Stock Chart & Stats
€13.30
€0.10(1.03%)
At close: 4:00 PM EST
€13.30
€0.10(1.03%)
Day’s Range― - ―
52-Week Range€11.85 - €13.90
Previous CloseN/A
Volume30.00
Average Volume (3M)3.00
Market Cap
€226.27M
Enterprise Value€225.13M
Total Cash (Recent Filing)€23.03M
Total Debt (Recent Filing)€16.28M
Price to Earnings (P/E)13.6
Beta0.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding17,036,577
10 Day Avg. Volume6
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)163.15
Price to Sales (P/S)89.18
P/FCF Ratio1.24K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.16
Revenue Forecast (FY)€270.70M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetBeing effectively unlevered provides durable financial flexibility: lower interest burden, more optionality for capex, dividends or bolt-on M&A, and greater resilience to cyclical shocks. Over the next 2–6 months this supports stable operations and strategic optionality.
Consistent Revenue GrowthMulti-year, steady top-line growth reflects durable product demand, recurring replacement/consumable dynamics and effective distribution into hospitals and clinics. This trend supports medium-term capacity planning and predictable revenue base for reinvestment.
Improved 2025 ProfitabilityMaterial margin recovery indicates better mix or cost control and demonstrates the business can extract operating leverage. Sustained higher margins enhance cash flow potential and ROE, underpinning durable earnings power if maintained versus prior volatility.
Bears Say
Uneven Cash GenerationIntermittent negative operating and free cash flow in prior years plus a 2025 FCF step-down versus 2024 signal that cash conversion is inconsistent. This reduces the reliability of internally funded growth and increases sensitivity to working-capital swings and capex over the medium term.
Margin VolatilityHistoric swings in gross and operating margins point to exposure to input costs, product mix or pricing pressures. Persistent volatility undermines forecast accuracy and margin sustainability, raising execution risk for translating revenue growth into stable profits.
Limited Return Expansion Without LeverageZero debt reduces financial risk but constrains one lever for boosting ROE and EPS growth. If operating improvements or market share gains stall, the company has less scope to accelerate returns via capital structure, potentially slowing medium-term earnings growth.
PRIM, S.A. News
0FP0 FAQ
What was PRIM, S.A.’s price range in the past 12 months?
PRIM, S.A. lowest share price was €11.85 and its highest was €13.90 in the past 12 months.
What is PRIM, S.A.’s market cap?
PRIM, S.A.’s market cap is €226.27M.
When is PRIM, S.A.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PRIM, S.A.’s earnings last quarter?
Currently, no data Available
Is PRIM, S.A. overvalued?
According to Wall Street analysts PRIM, S.A.’s price is currently Overvalued.
Does PRIM, S.A. pay dividends?
PRIM, S.A. does not currently pay dividends.
What is PRIM, S.A.’s EPS estimate?
PRIM, S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRIM, S.A. have?
PRIM, S.A. has 17,036,577 shares outstanding.
What happened to PRIM, S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PRIM, S.A.?
Currently, no hedge funds are holding shares in GB:0FP0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRIM, S.A.
Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassotherapy and hydrotherapy), rehabilitation, spa facilities, elderly care, and a range of supportive techniques, reaching customers within Spain and across global borders. Furthermore, the company supplies specialized goods for neuro-trauma, cardiovascular health, neuromodulation, surgical suites, endosurgical procedures, cosmetic surgery, and ear, nose, and throat (ENT) specialties. Beyond its product offerings, Prim, S.A. is involved in overseeing wellness developments, including hotel properties, vacation resorts, and athletic clubs. The firm was established in 1870 and maintains its principal office in Móstoles, Spain.
Technical Analysis
Oryzon Genomics SA
―
Pharma Mar SA
―
Atrys Health SA
―
Labiana Health SA
―
Santa Ana Global Enterprises SA
―